PBPaul Bresser

Paul Bresser

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Paul Bresser has a total of 61 co-authors. Here are the top co-authors by number of shared publications:

  • Mart N. van der Plas

    Department of Respiratory Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands

    4 shared publications
  • Herre J. Reesink

    Departments of Pulmonology Academic Medical Center, University of Amsterdam Amsterdam the Netherlands

    2 shared publications
  • Jaap J. Kloek

    Cardiothoracic Surgery Academic Medical Center, University of Amsterdam Amsterdam the Netherlands

    2 shared publications
  • Sulaiman Surie

    Departments of Pulmonology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands

    2 shared publications
  • Sulaiman Surie

    Department of Pulmonary Diseases, University of Amsterdam, Amsterdam, The Netherlands

    2 shared publications
  • Abu Shahed Md Zahed

    Department of Internal Medicine, Chittagong Medical College and Hospital (CMCH), Chittagong, Bangladesh.

    1 shared publication

Latest Publications

  • Open Access

    Expression of inhibitory regulators of innate immunity in patients with active tuberculosis

    by Dana C Blok, Liesbeth M Kager, Arie J Hoogendijk, Ivar O Lede, Wahid Rahman, Rumana Afroz, Paul Bresser, Jaring S van der Zee, Aniruddha Ghose, Caroline E Visser, et al.

    Tuberculosis (TB) is an important cause of morbidity and mortality worldwide. Toll-like-receptors (TLRs) are important for the recognition of the causative agent Mycobacterium tuberculosis. Negative regulation of TLRs is necessary to control deleterious inflammatory damage, but could provide a means of immune evasion by M. tuberculosis as well. To obtain insight in the extent of expression of inhibitory regulators of immunity in patients with active TB, peripheral-blood-mononuclear-cells (PBMCs) and plasma were obtained from 54 TB patients and 29 healthy blood donors from Chittagong, Bangladesh. Bilateral alveolar macrophages were obtained from an infected versus a contralateral normal lung segment of 9 patients. Statistical analyses were performed using Mann–Whitney U and Wilcoxon matched pairs testing. Correlations were calculated using the Spearman rho test. PBMCs harvested from TB patients demonstrated increased mRNA expression of IL-1-receptor-associated-kinase-M, suppressor-of-cytokine-signalling-3 and Toll-interacting-protein. Flow cytometry revealed enhanced expression of IL-1-receptor-like-1 (ST2) on lymphocytes. Plasma soluble ST2 was elevated in patients with TB and correlated with established TB biomarkers, most strongly with soluble interleukin-2 receptor subunit α and interleukin-8. Alveolar macrophage mRNA expression of negative TLR regulators did not differ between the infected and contralateral lung side. These results show enhanced expression of distinct negative regulators of innate immunity in PBMCs of patients with TB and identify plasma soluble ST2 as a potential novel biomarker for TB disease activity.


  • Open Access

    The receptor for advanced glycation end products in ventilator-induced lung injury

    by Maria T Kuipers, Hamid Aslami, Pieter Roel Tuinman, Anita M Tuip-De Boer, Geartsje Jongsma, Koenraad F van der Sluijs, Goda Choi, Esther K Wolthuis, Joris Jth Roelofs, Paul Bresser, et al.

    Mechanical ventilation (MV) can cause ventilator-induced lung injury (VILI). The innate immune response mediates this iatrogenic inflammatory condition. The receptor for advanced glycation end products (RAGE) is a multiligand receptor that can amplify immune and inflammatory responses. We hypothesized that RAGE signaling contributes to the pro-inflammatory state induced by MV. RAGE expression was analyzed in lung brush and lavage cells obtained from ventilated patients and lung tissue of ventilated mice. Healthy wild-type (WT) and RAGE knockout (KO) mice were ventilated with relatively low (approximately 7.5 ml/kg) or high (approximately 15 ml/kg) tidal volume. Positive end-expiratory pressure was set at 2 cm H2O during both MV strategies. Also, WT and RAGE KO mice with lipopolysaccharide (LPS)-induced lung injury were ventilated with the above described ventilation strategies. In separate experiments, the contribution of soluble RAGE, a RAGE isoform that may function as a decoy receptor, in ventilated RAGE KO mice was investigated. Lung wet-to-dry ratio, cell and neutrophil influx, cytokine and chemokine concentrations, total protein levels, soluble RAGE, and high-mobility group box 1 (HMGB1) presence in lung lavage fluid were analyzed. MV was associated with increased RAGE mRNA levels in both human lung brush samples and lung tissue of healthy mice. In healthy high tidal volume-ventilated mice, RAGE deficiency limited inflammatory cell influx. Other VILI parameters were not affected. In our second set of experiments where we compared RAGE KO and WT mice in a 2-hit model, we observed higher pulmonary cytokine and chemokine levels in RAGE KO mice undergoing LPS/high tidal volume MV as compared to WT mice. Third, in WT mice undergoing the LPS/high tidal volume MV, we observed HMGB1 presence in lung lavage fluid. Moreover, MV increased levels of soluble RAGE in lung lavage fluid, with the highest levels found in LPS/high tidal volume-ventilated mice. Administration of soluble RAGE to LPS/high tidal volume-ventilated RAGE KO mice attenuated the production of inflammatory mediators. RAGE was not a crucial contributor to the pro-inflammatory state induced by MV. However, the presence of sRAGE limited the production of pro-inflammatory mediators in our 2-hit model of LPS and high tidal volume MV.


  • Pulmonary vascular limitation to exercise and survival in idiopathic pulmonary fibrosis

    by Mart N. van der Plas, Coen van Kan, Judith Blumenthal, Henk M. Jansen, Athol U. Wells, Paul Bresser

    Background and objective: Pulmonary hypertension is frequently observed in advanced idiopathic pulmonary fibrosis (IPF) and is associated with poor prognosis. Cardiopulmonary exercise testing (CPET) can be used to detect less advanced pulmonary vascular impairment, and therefore may be of prognostic use. We studied the predictive value of non‐invasive exercise parameters that were associated with elevated systolic pulmonary artery pressure (sPAP) for survival in IPF patients.Methods: From our interstitial lung disease database, we reviewed records of consecutive patients with IPF in whom CPET and echocardiography were performed within 2 weeks (n = 38).Results: Eleven patients (29%) had increased sPAP (≥40 mm Hg). From all non‐invasive CPET parameters, only the ventilatory equivalent for CO2 (V'E/V'CO2) at anaerobic threshold differed significantly between patients with and without sPAP ≥ 40 mm Hg. The receiver‐operator characteristic curve for V'E/V'CO2 resulted in areas under the curve of 0.77 (95% CI: 0.569–0.970; P = 0.026), with a cut‐off value for predicting sPAP ≥ 40 mm Hg of >45.0. Patients with V'E/V'CO2 > 45.0 had significantly worse survival compared with patients with V'E/V'CO2 ≤ 45.0 (P = 0.001). In contrast, sPAP did not predict survival.Conclusions: V'E/V'CO2, the only CPET parameter associated with elevated sPAP, appears a potentially useful non‐invasive marker for early detection of pulmonary vascular impairment, and therefore may be of use for a more accurate prognostic assessment in IPF patients.


  • Bosentan Treatment Is Associated With Improvement of Right Ventricular Function and Remodeling in Chronic Thromboembolic Pulmonary Hypertension

    by Sulaiman Surie, Herre J. Reesink, J. Tim Marcus, Mart N. van der Plas, Jaap J. Kloek, Anton Vonk‐Noordegraaf, Paul Bresser

    Background Medical pretreatment before pulmonary endarterectomy (PEA) can optimize right ventricular (RV) function and may improve postoperative outcome in high‐risk patients. Using cardiac magnetic resonance imaging (cMRI), we determined whether the dual endothelin‐1 antagonist bosentan improves RV function and remodeling in patients with chronic thromboembolic pulmonary hypertension (CTEPH) who waited for PEA. Hypothesis We hypothesized that medical therapy prior to PEA will be associated with improvements in RV remodeling and function. Methods In this pilot study, 15 operable CTEPH patients were randomly assigned to either bosentan (n = 8) or no bosentan (n = 7, control) for 16 weeks, next to “best standard of care.” Both before and after treatment, RV stroke volume index (RVSVI), RV ejection fraction (RVEF), RV mass, RV isovolumic relaxation time (rIVRT), leftward ventricular septal bowing (LVSB), and left ventricular ejection fraction (LVEF) were determined using cMRI. Results After 16 weeks, the change (Δ) from baseline (median [range]) in the studied cMRI parameters differed significantly between the bosentan group and the controls: Δ RVSVI: 6 [−4–11] vs 1 [−6–3] mL/m−2; Δ RVEF: 8 [−10–15] vs −4 [−7–5]%; Δ RV mass: −3 [−6–−2] vs 2 [−1–3] g/m−2; Δ rIVRT: −30 [−130–20] vs 10 [−30–30] msec; Δ LVSB: 0.03 [−0.03–0.13] vs −0.03[−0.08–0.04] cm−1; and Δ LVEF: 8 [−5–17] vs −2 [−14–2]% (all P < 0.05). The change from baseline in mean pulmonary artery pressure (−11 [−17–11] vs 5 [−6–21] mm Hg, P < 0.05) and 6‐minute walk distance (20 [3–88] vs −4 [−40–40] m, P < 0.05) also differed significantly. Conclusions In CTEPH, compared with control, treatment with bosentan for 16 weeks was associated with a significant improvement in cMRI parameters of RV function and remodelling.


  • Open Access

    Plasma brain natriuretic peptide as a biomarker for haemodynamic outcome and mortality following pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension

    by Sulaiman Surie, Herre J. Reesink, Mart N. van der Plas, Maxim Hardziyenka, Jaap J. Kloek, Aeilko H. Zwinderman, Paul Bresser

    In chronic thromboembolic pulmonary hypertension (CTEPH), right ventricular (RV) dysfunction is associated with increased morbidity and mortality following pulmonary endarterectomy. Plasma brain natriuretic peptide (BNP) levels were previously shown to correlate with RV (dys)function. We hypothesized that BNP can be used as a non-invasive biomarker to identify patients at ‘high risk’ for postoperative morbidity and mortality. We studied the postoperative outcome in 73 consecutive patients. Patients were divided into three groups based on previously determined cut-off levels: BNP 48.5 pmol/l, indicating RV dysfunction (right ventricular ejection fraction 48.5 pmol/l was shown to be an independent predictor of ‘bad outcome’. Compared with BNP 48.5 pmol/l identified patients at higher risk for (all-cause) mortality (17 vs 0%; P = 0.009) and residual PH (56 vs 20%; P < 0.004). Also, the durations of mechanical ventilation and intensive care unit stay were significantly longer in patients with BNP >48.5 pmol/ml. Plasma BNP levels may be of use as a non-invasive biomarker reflecting RV dysfunction, next to other well-recognized (invasive) parameters, for better preoperative risk stratification of CTEPH patients.


  • Open Access

    Chronic Thromboembolic Pulmonary Hypertension: Effects of Pulmonary Endarterectomy

    by Coen van, Mart N. van der Plas, Jaap J., Herre J., Paul Bresser

    Authors: Coen van Kan, Mart N. van der Plas, Jaap J. Kloek, Herre J. Reesink and Paul Bresser

  • Open Access

    Pulmonary endarterectomy normalizes interventricular dyssynchrony and right ventricular systolic wall stress

    by Gert-Jan Mauritz, Anton Vonk-Noordegraaf, Taco Kind, Sulaiman Surie, Jaap J Kloek, Paul Bresser, Nabil Saouti, Joachim Bosboom, Nico Westerhof, J Tim Marcus


    • 1 January 2010
      • Vol. 154, A1452

    [Chronic thrombo-embolic pulmonary hypertension].

    by Sulaiman Surie, Otto M Van Delden, Jaap J Kloek, Paul Bresser

    Chronic thrombo-embolic pulmonary hypertension (CTEPH) was diagnosed in two patients, a man aged 55 years and a woman aged 54 years, who had both suffered an episode of pulmonary embolism. CTEPH is a rare but serious late complication of pulmonary embolism. If left untreated, it is a progressive disease with a poor prognosis. Pulmonary endarterectomy is the treatment of choice for CTEPH; both patients were treated successfully with this operation. In clinical practice patients are often initially misdiagnosed, due to unawareness of the condition, and are therefore subjected to a long delay before treatment. In the first patient the condition had not been recognised on CT scans. The second patient had initially been treated with psychotherapy for a suspected burn-out. All physicians involved in taking care of patients with pulmonary embolism, must be aware of this serious complication. Diagnosis and treatment of CTEPH require a high level of expertise.